|
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
1 |
[GO] |
2024―Apr―15 |
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials |
Dan-Yu Lin, Jianqiao Wang, Yu Gu, Donglin Zeng |
2 |
[GO] |
2024―Mrz―29 |
Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries |
Rafael Dal-Ré, Emmanuel Bottieau, Odile Launay, Frits R. Rosendaal, Brigitte Schwarzer-Daum |
3 |
[GO] |
2024―Feb―17 |
Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance |
Matthew J Gooden, Gina Norato, Katherine Landry, Sandra B Martin, Avindra Nath, Lauren Reoma |
4 |
[GO] |
2023―Dez―23 |
A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials |
William J Muller, Ravi Jhaveri, Taylor Heald-Sargent, Michelle L Macy, Nia Heard-Garris, Seema Shah, Erin Paquette |
5 |
[GO] |
2023―Nov―20 |
Evaluating whether the proportional odds models to analyse ordinal outcomes in COVID-19 clinical trials is providing clinically interpretable treatment effects: A systematic review |
Masuma Uddin, Nasir Z Bashir, Brennan C Kahan |
6 |
[GO] |
2023―Feb―11 |
Adapting international clinical trials during COVID-19 and beyond |
Kamala Thriemer, Tamiru Shibiru Degaga, Mohammad Shafiul Alam, Bipin Adhikari, Rupam Tripura, Mohammad Sharif Hossain, et al. (+16) Michael Christian, Najia K Ghanchi, Hellen Mnjala, Sophie Weston, Benedikt Ley, Angela Rumaseb, Dagimawie Tadesse, Tedla Teferi, Daniel Yilma, Grant Lee, Holger Unger, Inge Sutanto, Ayodhia Pitaloka Pasaribu, Prakash Ghimire, Mohammad Asim Beg, Ric N Price |
7 |
[GO] |
2023―Feb―06 |
Is it reasonable to label a trial as pragmatic whose investigatorsdo not? The UK RECOVERY COVID-19 trial case |
Rafael Dal-Ré |
8 |
[GO] |
2022―Dez―23 |
Navigating COVID-19 and related challenges to completing clinical trials: Lessons from the PATRIOT and STEP-UP randomized prevention trials |
Priscilla K Salovaara, Christine Li, Andrew Nicholson, Stuart R Lipsitz, Sundar Natarajan |
9 |
[GO] |
2022―Jul―27 |
Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters |
Victor DeGruttola, Ravi Goyal, Natasha K Martin, Rui Wang |
10 |
[GO] |
2022―Jul―02 |
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges |
Susan Halabi, Jinyi Zhou, Yijie He, Linda R Bressler, Adrian F Hernandez, Nicholas A Turner, Hwanhee Hong |
11 |
[GO] |
2021―Okt―11 |
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) |
Daniel D Murray, Abdel G Babiker, Jason V Baker, Christina E Barkauskas, Samuel M Brown, Christina C Chang, et al. (+22) Victoria J Davey, Annetine C Gelijns, Adit A Ginde, Birgit Grund, Elizabeth Higgs, Fleur Hudson, Virginia L Kan, H Clifford Lane, Thomas A Murray, Roger Paredes, Mahesh KB Parmar, Sarah Pett, Andrew N Phillips, Mark N Polizzotto, Cavan Reilly, Uriel Sandkovsky, Shweta Sharma, Marc Teitelbaum, B Taylor Thompson, Barnaby E Young, James D Neaton, Jens D Lundgren |
12 |
[GO] |
2021―Jul―03 |
What do we do with our under-enrolled single-center COVID-19 clinical trials? |
Shing M Lee, Denise Esserman, Ken Cheung, James Dziura, Peter Peduzzi, Magdalena Sobieszczyk |
13 |
[GO] |
2021―Jun―22 |
Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom |
M Estée Török, Benjamin R Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, et al. (+75) Rachel Bousfield, Charlotte Summers, Caroline Saunders, Zoe McIntyre, Helen Morris, Jo Piper, Gloria Calderon, Sarah Dennis, Tracy Assari, Anita Marguerie de Rotrou, Ashley Shaw, John Bradley, John O’Brien, Robert C Rintoul, Ian Smith, Ed Bullmore, Krishna Chatterjee, Carla Ribeiro, Lorinda Pickup, Ranalie de Jesus, Karen Brookes, Phoebe Vargas, Caroline McMahon, Chiara Macor, Ciro Pasquale, Areti Bermperi, Evgenia Kourampa, Marivic Fabiculcana, Julie Ann Zerudo, Vivien Mendoza, Stewart Fuller, Claire Glemas, Sharon Baker, Greta Lyons, Marina Bishop, Siobhan Coleman, Naomi Thomas, Vince Mlilo, Edward Stanton, Rachel Michel, Julie Philips, Heidi Rice, Lucie Garner, Francesca Rosa, Saji Victor, Julie Zamikula, Sue Mepham, Fatima Hajee, Juan Carlos Quijano-Campos, Laura Watson, Christopher Georgiou, Jieniean Worsley, Djamilla Shamtally-Amode, Ferishta Rahimi, Heather Jones, Isabel Cruz, Gayle Lindsay, Christian Sparke, Anna Chapman, Katie Keating-Fedders, Codie Fahey, Danielle Johnson, Lucy Worboys, Simone Hargreaves, Ashlea Bucke, Lindsay Carr, Jackie Hampshire, Tracy Richardson, Jenny Sharpe, Lynne Whitehead, Naval Vyse, Stephen Kelleher, Mary-Beth Sherwood, Vicki Hughes, Kim Giraud |
14 |
[GO] |
2021―Mai―27 |
COVID-19 vaccine trials: The potential for “hybrid” analyses |
Thomas R Fleming, Martha Nason, Philip R Krause, Ira M Longini, Ana-Maria Henao-Restrepo |
15 |
[GO] |
2021―Mai―20 |
A telehealth-based randomized controlled trial: A model for outpatient trials of off-label medications during the COVID-19 pandemic |
Salomeh Keyhani, J Daniel Kelly, Stephen Bent, W John Boscardin, Michael G Shlipak, Sam Leonard, et al. (+10) Ann Abraham, Emily Lum, Nicholas Lau, Charles Austin, Catherine E Oldenburg, Allan Zillich, Lenny Lopez, Ying Zhang, Tom Lietman, Dawn M Bravata |
16 |
[GO] |
2021―Feb―10 |
An ethics framework for consolidating and prioritizing COVID-19 clinical trials |
Michelle N Meyer, Luke Gelinas, Barbara E Bierer, Sara Chandros Hull, Steven Joffe, David Magnus, et al. (+6) Seema Mohapatra, Richard R Sharp, Kayte Spector-Bagdady, Jeremy Sugarman, Benjamin S Wilfond, Holly Fernandez Lynch |
17 |
[GO] |
2021―Feb―09 |
Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape |
Haley Hedlin, Ariadna Garcia, Yingjie Weng, Ziyuan He, Vandana Sundaram, Bryan Bunning, et al. (+7) Vidhya Balasubramanian, Kristen Cunanan, Kristopher Kapphahn, Santosh Gummidipundi, Natasha Purington, Mary Boulos, Manisha Desai |
18 |
[GO] |
2021―Feb―09 |
COVID-19 vaccine trials: The use of active controls and non-inferiority studies |
Thomas R Fleming, Philip R Krause, Martha Nason, Ira M Longini, Ana-Maria M Henao-Restrepo |
19 |
[GO] |
2021―Feb―05 |
Commentary on Meyers et al: Ethically prioritizing trials in the COVID-19 era - practical considerations |
Romana Hasnain-Wynia, Matthew DeCamp, Marilyn Coors |
20 |
[GO] |
2021―Jan―21 |
Reopening schools safely in the face of COVID-19: Can cluster randomized trials help? |
Charles Weijer, Karla Hemming, Spencer Phillips Hey, Holly Fernandez Lynch |
21 |
[GO] |
2020―Dez―16 |
Lack of harmonization of coronavirus disease ordinal scales |
Deborah A Zarin, Stephen Rosenfeld |
22 |
[GO] |
2020―Nov―24 |
Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19 |
James E Burns, Ffion E Carlin |
23 |
[GO] |
2020―Aug―20 |
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial |
Brett L Houston, Patrick R Lawler, Ewan C Goligher, Michael E Farkouh, Charlotte Bradbury, Marc Carrier, et al. (+21) Vlad Dzavik, Dean A Fergusson, Robert A Fowler, Jean-Phillippe Galanaud, Peter L Gross, Emily G McDonald, Mansoor Husain, Susan R Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S Slutsky, Alexis F Turgeon, Scott M Berry, Robert S Rosenson, Jorge Escobedo, Jose C Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski |
24 |
[GO] |
2020―Aug―20 |
COVID-19 impact on multi-site recruitment and enrollment |
Emma Strujo, Mechelle Sanders, Kevin Fiscella, Marie Thomas, Brent Johnson, Alex Deets, et al. (+7) Claudia Sanchez Lucas, Tameir Holder, Nina Johal, Amneris Luque, Andrea Cassells, Stephen Williams, Jonathan N Tobin |
25 |
[GO] |
2020―Aug―20 |
A concern about survival time as an endpoint in coronavirus disease 2019 clinical trials |
Kay See Tan |
26 |
[GO] |
2020―Jul―17 |
Endpoints for randomized controlled clinical trials for COVID-19 treatments |
Lori E Dodd, Dean Follmann, Jing Wang, Franz Koenig, Lisa L Korn, Christian Schoergenhofer, et al. (+9) Michael Proschan, Sally Hunsberger, Tyler Bonnett, Mat Makowski, Drifa Belhadi, Yeming Wang, Bin Cao, France Mentre, Thomas Jaki |
27 |
[GO] |
2020―Jul―15 |
Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic |
Steven Piantadosi |
28 |
[GO] |
2020―Jul―11 |
Editorial: Clinical trial design in the era of COVID-19 |
Colin B Begg, Mithat Gonen, Daniel F Heitjan |
29 |
[GO] |
2020―Jul―11 |
Clinical trials in the time of a pandemic |
Susan S Ellenberg |
|